SCHEMBL4569700

SCHEMBL4569700

CC(C)(C)C(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)C1O)(c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.61
PDE3A Q14432 1/20 0.61
SLC29A1 Q99808 1/20 0.61
POLA1 P09884 2/20 0.57
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
MTOR P42345 1/20 0.39
MDM2 Q00987 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
ST6GAL1 P15907 4/20 0.37
TSHR P16473 1/20 0.37
GLA P06280 1/20 0.37
ITGB3 P05106 1/20 0.36
ITGAV P06756 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20610798 1.00 PDE4D (0.61) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL4572235 0.93 PDE4D (0.59) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL25602072 0.86 PDE3A (0.71) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL25602076 0.86 PDE3A (0.71) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL20610823 0.86 PDE4D (0.47) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL31142479 0.82 PDE4D (0.61) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL4572226 0.82 PDE4D (0.61) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL15164231 0.82 POLA1 (0.43) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL382458 0.81 PDE3A (0.75) PDE4DPDE3ASLC29A1POLA1LMNA
SCHEMBL15788426 0.81 PDE3A (0.75) PDE4DPDE3ASLC29A1POLA1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160317673-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS (AL), INC. 2016-11-03 US disclosed
US-20150273074-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. 2015-10-01 US disclosed
US-8501899-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2013-08-06 US disclosed
US-20120123055-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. (US) 2012-05-17 US disclosed
US-8101706-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2012-01-24 US disclosed
US-20100330023-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same SERINA THERAPEUTICS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160317673-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 PDE4D 1858/4885PDE3A 1081/4885SLC29A1 3216/4885
US-20100330023-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 PDE4D 1858/4885PDE3A 1081/4885SLC29A1 3216/4885
US-20150273074-A1 Multifunctional Forms of Polyoxazoline Copolymers and Drug Compositions Comprising the Same ERBB3, ERBB2, PANK2 PDE4D 1883/4885PDE3A 1086/4885SLC29A1 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.